2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2831

Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
Abstract Number: 1252

Real-World Oral Methotrexate Adherence Measured Electronically in Patients with Established Rheumatoid Arthritis
Abstract Number: 1524

Real-World Use of Secukinumab Among Biologic-NaïVe and Biologic-Experienced Patients with Ankylosing Spondylitis in the United States
Abstract Number: 1041

Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US
Abstract Number: 2223

Reallocating Time Spent in Sleep, Sedentary Behavior and Physical Activity and Its Association with Pain and Depression
Abstract Number: 280

Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Abstract Number: 2791

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
Abstract Number: 21

Reciprocal Regulation of B Cells on Bleomycin-Induced Scleroderma Model: IL-6-Producing Effector B Cells Play a Pathogenic Role, While IL-10-Producing Regulatory B Cells Play a Protective Role
Abstract Number: 2732

Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Abstract Number: 2395

Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements
Abstract Number: 437

Recruitment of RA Trials in the Modern Era: Are United States-Based Trials Still Feasible?
Abstract Number: 653

Reduced Ubiquitination of Misfolded HLA-B27 Is Associated with Inefficient Degradation By ERAD and Autophagy
Abstract Number: 1201

Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis
Abstract Number: 502

Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo
Abstract Number: 2676

Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].